Positive Phase 2 Study: Celldex Therapeutics revealed positive outcomes from a Phase 2 study of Barzolvolimab, focusing on patients with moderate to severe chronic spontaneous urticaria (CSU) refractory.
Well-Tolerated and Favorable Safety Profile: Barzolvolimab demonstrated general well-tolerance and exhibited a favorable safety profile in the study.
Transformative Potential: CEO Anthony Marucci highlighted the potential transformative role of Barzolvolimab as a treatment option for patients suffering from CSU.
Technical Analysis:
Support Level: The analysis suggests a support level above $35.00-$36.00, indicating a potential floor for price movements. Upside Target: The upside target is set in the range of $56.00-$58.00, reflecting positive expectations for Celldex Therapeutics.